Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC

Published:2002-10-17 Issue:3 Volume:53 Page:183-191
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Neeley Yilin C.,McDonagh Kevin T.,Overwijk Willem W.,Restifo Nicholas P.,Sanda Martin G.

Publisher

Wiley

Subject

Urology,Oncology

Reference33 articles.

1. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression.

2. Loss of HLA class I expression in prostate cancer: Implications for immunotherapy

3. MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peptide Modification Diminishes HLA Class II-restricted CD4+ T Cell Recognition of Prostate Cancer Cells;International Journal of Molecular Sciences;2022-12-03

2. Lysophospholipid Signalling and the Tumour Microenvironment;Advances in Experimental Medicine and Biology;2020-10-30

3. La inmunoterapia en la búsqueda de antígenos contra las células madre del cáncer;Inmunología;2014-07

4. Dendritic Cell Based PSMA Immunotherapy for Prostate Cancer Using a CD40-Targeted Adenovirus Vector;PLoS ONE;2012-10-08

5. Reduction of major histocompatibility complex class I expression on bladder carcinoma following tumor antigen-pulsed dendritic cell vaccine: Implications for immunoresistance in therapy;International Journal of Urology;2010-05-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP